Genomma Lab Reports Mixed Q2 2026 Results Amid Market Recovery
Genomma Lab Internacional reported a 3.6% decline in like-for-like sales for the second quarter of 2026, as the company navigated a soft retail environment in Mexico and the US. Despite the top-line contraction, the pharmaceutical group managed a 5.5% increase in net income, bolstered by improved margins and reduced financial expenses.
CEO Marco Sparvieri noted that while the company faced continued market headwinds, its core business units maintained or expanded market share. The gross margin saw a 106 basis-point improvement, reaching 64.6%, as productivity gains effectively absorbed higher promotional spending and new tax burdens on sweetened beverages. Performance varied by region, with Latin American operations recording 3.9% growth, which partially offset the ongoing disruption within the US Hispanic market.
Consolidated net sales totaled 4,397 million Mexican pesos, reflecting a 6.0% decrease compared to the same period in 2025, a figure further impacted by the 10.8% appreciation of the Mexican peso. While operating income and EBITDA faced pressure due to operational deleverage, the company remains optimistic about a second-half recovery. This confidence is driven by a new innovation pipeline, including the rollout of Suerox Mineral, which has already shown positive sell-out trends in early July. Management will discuss these results and future outlook during a scheduled conference call on July 23.
Comments (0)
No comments yet. Be the first!